Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamid and Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia.

Trial Profile

Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamid and Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Antithymocyte globulin; Busulfan; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Tacrolimus
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Jan 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top